NEW_CURA-LEAF_1170x120_OCT

Addyi

Valeant to buy Sprout Pharmaceuticals for $1 billion

Valeant to buy Sprout Pharmaceuticals for $1 billion

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. plans to acquire Sprout Pharmaceuticals Inc., the maker of a just-approved drug for sexual desire disorder in women, for about $1 billion in cash. Valeant said Thursday that it expects to close the deal in the third quarter of this year, pending customary closing conditions and regulatory approval.

FDA OKs first drug for women’s sexual desire disorder

FDA OKs first drug for women’s sexual desire disorder

RALEIGH, N.C. — Sprout Pharmaceuticals Inc. has gained Food and Drug Administration clearance to market Addyi, which the company calls the first FDA-approved medication for hypoactive sexual desire disorder (HSDD) in women. Sprout said late Tuesday that Addyi (flibanserin, 100 mg) is slated to be released by Oct. 17. “It has been a remarkable journey to